At AASLD 2020 virtual liver conference, Dr. Gideon Hirschfield presented promising Phase 3 results for Seladelpar a treatment for patients with PBC. Positive outcomes included: 78% of those in the study achieved primary (composite) endpoint at 3 months, ALP normalization and improvement in pruritus.
August 21, 2026
No Comments
